<PAGE>
- -------------------------------------------------------------------------------
- -------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
------------------
Date of Report (Date of earliest event reported): December 6, 1998
------------------
AVECOR CARDIOVASCULAR INC.
(Exact name of registrant as specified in its charter)
Minnesota 0-21330 41-1695729
(State of or other (Commission (I.R.S. Employer
jurisdiction of incorporation) File Number) Identification No.)
7611 Northland Drive, Minneapolis, Minnesota 55428
(Address of principal executive offices) (zip code)
Registrant's telephone number, including area code: (612) 391-9000
- -------------------------------------------------------------------------------
- -------------------------------------------------------------------------------
<PAGE>
ITEM 5. OTHER EVENTS.
On December 6, 1998, AVECOR Cardiovascular Inc. and Medtronic, Inc.
executed an amendment to the Agreement and Plan of Merger dated July 12, 1998
among AVECOR, Medtronic and Medtronic's acquisition subsidiary (the "Merger
Agreement"). Among other terms, the amendment increases the amount of Medtronic
stock AVECOR shareholders will receive in the merger in exchange for their
shares, providing for $13 in Medtronic stock to be issued for each share of
AVECOR stock instead of the $11.125 stock consideration provided for under the
original terms of the Merger Agreement.
The amendment also eliminates provisions of the Merger Agreement which
allowed AVECOR's Board of Directors, under certain circumstances, to furnish
information to and enter into discussions with any party making an unsolicited
offer for an alternative transaction, and to terminate the Merger Agreement
under certain circumstances in favor of an alternative transaction. The
amendment provides that Medtronic will make an interest-free, unsecured,
subordinated loan of $10 million to AVECOR in the event that the merger
transaction is not completed by March 15, 1999 as a result of failure of the
transaction to receive clearance under Hart-Scott-Rodino Act by that date.
AVECOR would be required to repay the loan to Medtronic if by March 15, 2000
AVECOR agreed to be acquired by another party at a price of at least $13.00 per
share of AVECOR stock. If the subsequent transaction was at a price less than
$13.00 per share of AVECOR stock, then the loan would be due and payable only in
an amount equal to the aggregate difference between $13.00 and the per share
price to be received by AVECOR's shareholders in the subsequent transaction. If
AVECOR did not enter into an agreement for a subsequent transaction by March 15,
2000 or if the price to be paid for AVECOR shares in the subsequent transaction
was below a certain level, then Medtronic would forgive the entire amount of the
loan on that date.
A copy of the amendment and AVECOR's press release regarding the amendment
are included as exhibits to this report and are incorporated herein by
reference.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(a) FINANCIAL STATEMENTS OF BUSINESSES ACQUIRED.
Not applicable.
(b) PRO FORMA FINANCIAL INFORMATION.
Not applicable.
(c) EXHIBITS.
2.1 Amendment to Agreement and Plan of Merger by and among AVECOR
Cardiovascular Inc., AC Merger Corp. and Medtronic, Inc. dated
December 6, 1998.
99.1 Press Release, dated December 6, 1998.
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
AVECOR CARDIOVASCULAR INC.
Dated: December 16, 1998 By /s/ Gregory J. Melsen
-------------------------------------
Gregory J. Melsen
Vice President - Finance, Treasurer
and Chief Financial Officer
3
<PAGE>
INDEX TO EXHIBITS
<TABLE>
<CAPTION>
Exhibit Item Method of Filing
- ------- ---- ----------------
<C> <S> <C>
2.1 Amendment to Agreement and Plan of Merger by and
among AVECOR Cardiovascular Inc., AC Merger Corp.
and Medtronic, Inc. dated December 6, 1998. ..... Filed herewith electronically
99.1 Press Release, dated December 6, 1998............. Filed herewith electronically
</TABLE>
4
<PAGE>
EXHIBIT 2.1
AMENDMENT TO AGREEMENT AND PLAN OF MERGER
This Amendment to Agreement and Plan of Merger (the "Amendment") is
entered into this sixth day of December, 1998 by and among MEDTRONIC, INC., a
Minnesota corporation ("Parent"), AC MERGER CORP., a Minnesota corporation
and wholly-owned subsidiary of Parent ("Merger Subsidiary"), and AVECOR
CARDIOVASCULAR INC., a Minnesota corporation (the "Company")
WHEREAS, the Parent, Merger Subsidiary and the Company are parties to an
Agreement and Plan of Merger dated as of July 12, 1998 (the "Agreement"); and
WHEREAS, the Company's shareholders approved the Agreement and the related
Plan of Merger at a Special Meeting of Shareholders held on October 28, 1998;
and
WHEREAS, following the shareholder approval, the Company received a letter
dated November 23, 1998 from a third party making an offer to acquire the
Company (the "Third Party Offeror") and engaged in discussions with the Third
Party Offeror regarding the Third Party Offeror's proposal to acquire all of the
Company's outstanding Common Stock at a price of $13 per share, payable in cash
or stock (the "Alternative Offer"); and
WHEREAS, after careful consideration of the Alternative Offer and
discussions with Parent regarding the terms of this Amendment, the Company's
Board of Directors has elected to terminate its discussions with Third Party
Offeror and refrain from discussions with any other party seeking to acquire the
Company, in order to secure for the benefit of the Company's shareholders the
amended transaction with Parent and AC Merger Corp. as set forth in the
Amendment; and
WHEREAS, the parties hereto desire to amend the Agreement as set forth in
this Amendment;
NOW, THEREFORE, in consideration of the foregoing premises and the mutual
agreements, provisions and covenants contained in this Amendment, the parties
hereto agree as follows:
1. Section 1.3(a) of the Agreement is hereby amended to read in its
entirety as follows:
1.3 CONVERSION OF SHARES. At the Effective Time, by virtue of
the Merger and without any action on the part of any holder of any
share of capital stock of the Company or Merger Subsidiary:
<PAGE>
(a) Each share of common stock of the Company, par value $.01
per share ("Company Common Stock"), issued and outstanding immediately
prior thereto (except for Dissenting Shares, as defined in Section 1.4
hereof, and except for shares referred to in Section 1.3(b) hereof)
shall be converted into the right to receive the fraction of a share
(subject to adjustment as provided below, the "Conversion Fraction")
of common stock of Parent, par value $.10 per share ("Parent Common
Stock"), equal to $13 divided by the Parent Average Stock Price. The
"Parent Average Stock Price" shall mean the average (rounded to the
nearest full cent, with the cents rounded up if the third decimal
place is 5 or more) of the daily closing sale prices of a share of
Parent Common Stock as reported on the New York Stock Exchange
("NYSE") Composite Tape, as reported in The Wall Street Journal, for
the 18 consecutive NYSE trading days ending on and including the
second NYSE trading day immediately preceding the Effective Time.
Notwithstanding the foregoing, if the sum of the number of shares
of Company Common Stock outstanding immediately prior to the Effective
Time plus the number of shares subject to then outstanding options,
warrants, or other rights to acquire shares of Company Common Stock
(collectively, "Company Stock Acquisition Rights") is greater than
8,879,725 shares plus that number of shares issuable pursuant to the
offering period in process as of July 12, 1998 under the Company's
Employee Stock Purchase Plan or if the aggregate exercise price of all
such Company Stock Acquisition Rights then outstanding is less than
the aggregate exercise price reflected in Section 3.4 hereof, then the
$13 amount per share of Company Common Stock, as described above,
shall be reduced to an amount, if lower, equal to (i) $13 times
[8,879,725 shares plus that number of shares issuable pursuant to the
offering period in process as of July 12, 1998 under the Company's
Employee Stock Purchase Plan] minus the aggregate exercise price
reflected in Section 3.4 hereof plus the aggregate amount received by
the Company as a result of any issuance of Company Common Stock after
the date of this Agreement and prior to the Effective Time plus the
aggregate exercise price of all Company Stock Acquisition Rights
outstanding immediately prior to the Effective Time divided by
(ii) the sum of (A) the number of shares of Company Common Stock
outstanding immediately prior to the Effective Time plus (B) the
number of shares subject to Company Stock Acquisition Rights then
outstanding.
An appropriate adjustment shall similarly be made in the event
that, prior to the Effective Time, the outstanding shares of Company
Common Stock, without new consideration, are changed into or exchanged
for a different kind of shares or securities through a reorganization,
reclassification, stock dividend, stock combination, or other like
change in the Company's capitalization. Notwithstanding the
foregoing, nothing in this section shall be deemed to constitute
authorization or permission for or consent from Parent or Merger
2
<PAGE>
Subsidiary to any increase in the number of shares of Company Common
Stock outstanding or subject to outstanding Company Stock Acquisition
Rights, to any decrease in the exercise price of such Rights, or to
any reorganization, reclassification, stock dividend, stock
combination, or other like change in capitalization.
2. Article 2, "Closing" of the Agreement is hereby amended to add a new
Section 2.3 which shall read as follows:
2.3 PAYMENT ON FAILURE TO CLOSE.
(a) If the Closing does not occur on or before March 15, 1999
because the condition set forth in Section 6.1(e) has not been
fulfilled (without regard to the limitation on the obligations of
Parent and Merger Subsidiary set forth in the last sentence of Section
5.9) and notwithstanding any other provision of this Agreement to the
contrary, then Parent will advance to the Company on such date (by
wire transfer of immediately available funds to an account designated
by the Company for this purpose) an amount equal to $10 million as an
unsecured, interest-free loan (the "Failure to Close Loan"); provided,
however, that Parent shall not be required to provide the Failure to
Close Loan if the Company has intentionally and knowingly taken any
action in breach of any provision of this Agreement, or intentionally
and knowingly failed to take any action required to be taken by it
pursuant to any provision of this Agreement, which causes or results
in the failure to satisfy the condition set forth in Section 6.1(e).
The Failure to Close Loan shall be subordinated to the prior payment
of any other obligations of the Company. The purpose of the Failure to
Close Loan is to recognize the time, efforts and expenses expended and
incurred by the Company with respect to the transactions contemplated
by this Agreement, the Company's willingness to terminate its
discussions with the Third Party Offeror and agree to the terms of
this Amendment (including without limitation the amendment of Section
5.2 and the deletion of Section 7.1(f)) and the detriment likely to be
suffered by the Company and its shareholders if the Merger is not
completed. In the event that there is any dispute over whether or not
Parent is obligated to make the Failure to Close Loan pursuant to this
Section 2.3, Parent agrees that it shall deposit $10 million into an
escrow account upon the institution by either the Company or Parent of
any litigation, arbitration or other alternative dispute procedures
related to this Section 2.3. The Failure to Close Loan shall be
repaid to Parent or forgiven by Parent in the manner set forth in
subparagraph (b) below notwithstanding any other language in this
Section 2.3 regarding the subordination of the Failure to Close Loan
or any other restrictions arising from other agreements, including
loan agreements or other debt instruments, to which the Company may be
a party. The Company will not be obligated to pay any interest to
Parent or otherwise in respect of the Failure to Close Loan.
3
<PAGE>
(b) If the Company on or before March 15, 2000 enters into an
agreement with any entity or group (other than Parent or any affiliate
or agent of Parent) with respect to a merger, share exchange or other
business combination, including without limitation a tender offer for
all of the Company's outstanding capital stock, which provides the
Company's shareholders the opportunity to sell all of their shares or
convert all of their shares to equity in the acquiring entity (a
"Subsequent Transaction") at a price or value per share of Company
Common Stock equal to or greater than $13.00 per share (as adjusted
pursuant to Section 1.3(a) hereof), then immediately upon entering
into an agreement providing for such a Subsequent Transaction the
Company shall repay to Parent the Failure to Close Loan. If the
Company on or before March 15, 2000 enters into an agreement for a
Subsequent Transaction which offers its shareholders less than $13.00
per share (as adjusted pursuant to Section 1.3(a) hereof), then
immediately upon entering into an agreement providing for such a
Subsequent Transaction the Company shall repay to Parent a portion of
the Failure to Close Loan equal to $10 million less the product of (x)
the difference between the $13.00 per share (as adjusted pursuant to
Section 1.3(a) hereof) and the per share price to be paid in the
Subsequent Transaction, multiplied by (y) the number of outstanding
shares of the Company's Common Stock on the date of the agreement for
the Subsequent Transaction, and Parent shall forgive the repayment of
the balance of the Failure to Close Loan. If the Company does not
enter into an agreement for a Subsequent Transaction on or before
March 15, 2000, then on March 15, 2000 Parent shall forgive the
repayment of the full amount of the Failure to Close Loan. For
purposes of this paragraph, any non-cash consideration paid to the
Company's shareholders by an acquiring entity (a) shall be, in the
case of capital stock of the acquiring entity, valued based upon the
market value on the date an agreement providing for a Subsequent
Transaction is entered into, and (b) shall be, in the case of any
other non-cash consideration, valued as determined in good faith by
the Company based on the written opinion of the Company's investment
banker.
(c) Parent acknowledges that the agreements contained in this
Section 2.3 are an integral part of the transactions contemplated by
this Amendment and this Agreement and are not a penalty, and that,
without these agreements, the Company would not enter into this
Amendment. The Company and Parent acknowledge that the Company will
suffer irreparable harm if Parent does not pay the Company the Failure
to Close Payment pursuant to subsection (a) above and that Parent will
suffer irreparable harm if the Company proceeds with a Subsequent
Transaction without repaying to Parent any amounts due to Parent
pursuant to subsection (b) above. Accordingly, either party shall be
entitled, in addition to any other right or remedy it may have at law
or in equity, to an injunction, without the posting of a bond or other
security, to enforce the foregoing provisions of this Section.
3. Section 5.2 of the Agreement is hereby amended to read in its entirely
as follows:
4
<PAGE>
5.2 NO SOLICITATION. From the date hereof until the termination
of this Agreement, the Company will not and will cause its
Subsidiaries and its and their respective officers, directors,
employees, representatives, agents, or affiliates (including, but not
limited to any investment banker, attorney, or accountant retained by
the Company or any Subsidiary), to not, directly or indirectly,
solicit, encourage, initiate, or participate in any way in discussions
or negotiations with, or knowingly provide any information to, any
corporation, partnership, person, or other entity or group (other than
Parent or any affiliate or agent of Parent) concerning any merger,
sale or licensing of any significant portion of the assets, sale of
shares of capital stock (including without limitation any proposal or
offer to the Company's shareholders), or similar transactions
involving the Company or any Subsidiary (an "Alternative Proposal"),
or otherwise facilitate any effort or attempt to make or implement an
Alternative Proposal. The Company will promptly communicate to Parent
the terms of any proposal or inquiry that it has received or may
receive in respect of any such transaction or of any such information
requested from it or of any such negotiations or discussions being
sought to be initiated with the Company and may inform any third party
who contacts the Company on an unsolicited basis concerning an
Alternative Proposal that the Company is obligated hereunder to
disclose such to Parent. Nothing in this section shall (x) permit the
Company to terminate this Agreement (except as specifically provided
in Article 7 hereof), (y) permit the Company to enter into any
agreement with respect to an Alternative Proposal for as long as this
Agreement remains in effect (it being agreed that for as long as this
Agreement remains in effect, the Company shall not enter into any
agreement with any person that provides for, or in any way
facilitates, an Alternative Proposal), or (z) affect any other
obligation of the Company under this Agreement while this Agreement
remains in effect.
4. Article 5 of the Agreement is hereby amended to add a new Section 5.20
to read as follows:
5.20 SHAREHOLDER APPROVAL. Parent and Company agree that the approval
of the Agreement by the Company's shareholders on October 28, 1998 is
sufficient to authorize the Plan of Merger as amended by this Amendment
without further shareholder approval.
5. Section 6.2(a) of the Agreement is hereby amended to delete the period
at the end of such section and add the following:
and except for any inaccuracies that, individually or in the
aggregate, have a Company Material Adverse Effect known to the Parent as of
the date of this Amendment.
6. Section 6.3(a) of the Agreement is hereby amended to delete the period
at the end of such section and add the following:
5
<PAGE>
and except for any inaccuracies that, individually or in the
aggregate, have a Parent Material Adverse Effect known to the Company as of
the date of this Amendment.
7. Section 7.1(b) of the Agreement is hereby amended to read in its
entirety as follows:
(b) by either Parent or the Company if the Merger shall not have
been consummated on or before March 15, 1999; provided, however, that
the terminating party shall not have breached in any material respect
its obligations under this Agreement in any manner that shall have
been the proximate cause of, or resulted in, the failure to consummate
the Merger by such date.
8. Section 7.1(d) of the Agreement is hereby deleted and should be
replaced as follows:
(d) [Intentionally Omitted]
9. Section 7.1(e) of the Agreement is hereby amended to read in its
entirety as follows:
(e) by Parent if any of the following actions are taken by the
Company or its Board of Directors on the basis of a final court
determination that the Company or its Board of Directors are obligated to
do so notwithstanding the prohibitions of this Agreement: (i) the Company
has not complied with its obligations under Section 5.2 in any material
respect, (ii) the Board of Directors of the Company has recommended,
approved, accepted, or entered into an agreement regarding, an Alternative
Proposal, as defined in Section 5.2, (iii) the Board of Directors of the
Company has withdrawn or modified in a manner adverse to Parent its
recommendation of the Merger, or (iv) a tender offer or exchange offer for
15% or more of the outstanding shares of Company Common Stock is commenced,
and the Board of Directors of the Company, within 10 business days after
such tender offer or exchange offer is so commenced, either fails to
recommend against acceptance of such tender offer or exchange offer by its
shareholders or takes no position with respect to the acceptance of such
tender offer or exchange offer by its shareholders;
10. Section 7.1(f) of the Agreement is hereby deleted and should be
replaced as follows:
(f) [Intentionally Omitted]
11. Section 7.1(g) of the Agreement is hereby amended to read in its
entirety as follows:
(g) by Parent if (i) Parent is not in material breach of its
obligations under this Agreement and (ii) there has been (x) a material
breach by the Company of any of its
6
<PAGE>
representations, warranties, or obligations under this Agreement or by
an Affiliate of the Company under such person's affiliate's letter
described in Section 5.6 or by an office or director of the Company
under such person's Agreement to Facilitate Merger described in Section
5.11 not known to Parent as of December 6, 1998, such that the
conditions in Section 6.2 will not be satisfied, and the breach is not
curable or, if curable, is not cured by the Company within 30 calendar
days after receipt of the Company of written notice from Parent of such
breach or (y) a willful and material breach by the Company of any of its
representations, warranties, or obligations under this Agreement or by
an Affiliate of the Company under such person's affiliate's letter
described in Section 5.6 or by an office or director of the Company
under such person's Agreement to Facilitate Merger described in Section
5.11 arising after December 6, 1998, such that the conditions in Section
6.2 will not be satisfied, and such breach is not curable or, if
curable, is not cured by the Company within 30 calendar days after
receipt of the Company of written notice from Parent of such breach (for
purposes of this Section 7.1(g), a willful and material breach shall be
deemed to have occurred if the Company or an Affiliate, as the case may
be, has intentionally and knowingly taken, or intentionally and
knowingly failed to take, any action which causes such material breach);
12. Section 7.1(h) of the Agreement is hereby amended to read in its
entirety as follows:
(h) by the Company if (i) the Company is not in material breach of
its obligations under this Agreement and (ii) there has been (x) a material
breach by Parent of any of its representations, warranties, or obligations
under this Agreement not known to the Company as of December 6, 1998, such
that the conditions in Section 6.3 will not be satisfied, and the breach is
not curable or, if curable, is not cured by Parent within 30 calendar days
after receipt by Parent of written notice from the Company of such breach
or (y) a willful and material breach by Parent of any of its
representations, warranties, or obligations under this Agreement arising
after December 6, 1998, such that the conditions in Section 6.3 will not be
satisfied, and such breach is not curable or, if curable, is not cured by
Parent within 30 calendar days after receipt by Parent of written notice
from the Company of such breach (for purposes of this Section 7.1(h), a
willful and material breach shall be deemed to have occurred if Parent has
intentionally and knowingly taken, or intentionally and knowingly failed to
take, any action which causes such material breach).
13. Section 7.2(a) of the Agreement is hereby amended to read in its
entirety as follows:
7.2 EFFECT OF TERMINATION
(a) In recognition of the time, efforts, and expenses expended
and incurred by Parent with respect to the Company and the opportunity
that the acquisition of the Company presents to Parent, if this
Agreement is terminated pursuant to Section 7.1(e) or if there is a
final court determination that the
7
<PAGE>
Company or its Board is obligated to take any of the actions referenced
in Section 7.1(e) and the Company or its Board does so, then the Company
will pay to Parent immediately upon the date of entering into an
agreement providing for an Alternative Proposal (if such agreement is
entered into within 12 months of the termination of this Agreement or of
the Company or the Board taking any such actions referenced in Section
7.1(e)), by wire transfer of immediately available funds to an account
designated by Parent for such purpose, a fee equal to $2.75 million.
The Company acknowledges that the agreements contained in this Section
7.2 are an integral part of the transactions contemplated by this
Agreement and are not a penalty, and that, without these agreements,
Parent would not enter into this Agreement. If the Company fails to pay
promptly the fee due pursuant to this Section 7.2, the Company shall
also pay to Parent Parent's costs and expenses (including legal fees and
expenses) in connection with any action, including the filing of any
lawsuit or other legal action, taken to collect payment, together with
interest on the amount of the unpaid fee under this section, accruing
from its due date, at an interest rate per annum equal to two percentage
points in excess of the prime commercial lending rate quoted by Norwest
Bank Minnesota, N.A. Any change in the interest rate hereunder
resulting from a change in such prime rate shall be effective at the
beginning of the day of such change in such prime rate.
14. Except as expressly set forth herein, the Merger Agreement shall
remain in full force and effect.
15. This Amendment may be executed in any number of counterparts, each of
which shall be deemed an original and all of which together shall constitute one
instrument.
IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of
the date first above written.
AVECOR CARDIOVASCULAR, INC. MEDTRONIC, INC.
By: /s/ Anthony Badolato By /s/ Michael D. Ellwein
------------------------------- -------------------------------
Its: CEO Its: Vice President
AC MERGER CORP.
By /s/ Michael D. Ellwein
-------------------------------
Its: President
8
<PAGE>
EXHIBIT 99.1
FROM: FOR:
Swenson NHB Investor Relations AVECOR Cardiovascular Inc.
1300 Fifth Street Towers, 150 S. 5th St. 7611 Northland Drive
Minneapolis, Minn. 55402 Minneapolis, Minn. 55428
Contact: Curt Swenson 612.344.1021 Contact: Greg Melsen 612.391.9000
FOR IMMEDIATE RELEASE
MEDTRONIC AND AVECOR AMEND MERGER AGREEMENT,
INCREASING ACQUISITION PRICE TO $13 PER SHARE
MINNEAPOLIS, Dec. 6 -- AVECOR Cardiovascular Inc. (Nasdaq:AVEC) and
Medtronic, Inc. (NYSE:MDT), announced today an amendment to their merger
agreement that increases the amount of Medtronic stock AVECOR holders will
receive in exchange for their shares. The amended agreement calls for $13 in
Medtronic stock to be issued for each share of AVECOR, up from $11.125 in the
original agreement signed in July and approved by AVECOR shareholders on Oct.
28.
The amended agreement also calls for Medtronic to pay AVECOR up to $10
million if the merger is not completed by March 15, 1999, by reason of the
failure to obtain FTC clearance by that date.
AVECOR's board has agreed that it will not explore alternative
acquisition proposals, and Medtronic has agreed to drop its suit that sought
to prevent AVECOR from exploring an unsolicited offer it received last month.
On Nov. 23, AVECOR had received an unsolicited $13 offer from another medical
device manufacturer. During the following 10 days, AVECOR discussed a
possible transaction with this party. As provided by the amended agreement
with Medtronic, AVECOR has ceased discussions with the other party.
"We are pleased to have reached this agreement, which increases the
value of the transaction to our shareholders and eliminates the delays and
uncertainties that would have accompanied continued litigation," said Anthony
Badolato, AVECOR chairman and chief executive officer. "While we continue to
be involved in ongoing negotiations with the Federal Trade Commission
concerning the FTC request for additional information under the
Hart-Scott-Rodino Act, we remain optimistic that the FTC's concerns can be
successfully resolved."
9
<PAGE>
AVECOR Cardiovascular Inc., headquartered in Minneapolis, develops,
manufactures and markets specialty disposable medical devices for heart/lung
bypass surgery and long-term respiratory support. The company's current products
include membrane oxygenators, blood pumps, blood reservoirs, blood filters,
cardioplegia systems and custom tubing packs.
Medtronic, also headquartered in Minneapolis, is the world's leading
medical technology company specializing in implantable and interventional
therapies.
# # # #
12/06/98
10
